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Intravenous (IV) busulfan (BU) gives more predictable exposure
than the oral form and is easier to administer once daily than the
conventional four times daily schedule. Fludarabine is immuno-
suppressive, antileukaemic and perhaps better tolerated than cy-
clophosphamide. Low-dose pretransplant ATG appears to reduce
morbidity and mortality of graft-versus-host disease (GVHD). A
conditioning regimen incorporating these agents appears well tol-
erated and adding a low dose of total body irradiation (TBI) does
not seem to increase non-relapse mortality. This regimen was
given to a total of 64 acute leukemia patients (pts) aged 18-63
(median 40) years of whom 28 (44%) had ALL or lymphoblastic
lymphoma (n  2) in CR1 (n  22) or CR2 (n  6), and 36 (66%)
had AML (25 CR1, 11 CR2). Donors were matched siblings
(MRD) for 31 (48%) and alternate donors (AD, 28 unrelated and
5 mismatched related) for 33 (52%). Cell source was blood in all
MRD and 26 (76%) AD pts. All pts received ﬂudarabine 50 mg/m2
on days 6 to 2 and IV BU (Busulfex, ESP Pharma) at a
“myeloablative” dose of 3.2 mg/kg daily days 5 to 2 inclusive
and TBI 200 cGy  2 on day 1 or 0. Prophylaxis for GVHD was
cyclosporine A, “short course” methotrexate with folinic acid and
Thymoglobulin (Genzyme) 4.5 mg/kg in divided doses over 3
consecutive days pretransplant ﬁnishing day 0. Follow-up of sur-
vivors is 3-64 months, median 20. After MRD and AD transplants
the incidence of acute GVHD grade II-IV was 11  6% vs 35 
9% (P  .047), acute GVHD grade III-IV was 0% vs 10  6%
(P  .09) and chronic GVHD was 46  10% vs 73  9% (P  ns)
respectively. There were 3 transplant-related deaths, only in ALL
patients, one each from acute GVHD, pneumonitis and PTLD
giving an overall TRM of 5  3%. Of 6 relapsing pts with ALL 4
are in a further remission after a second myeloablative transplant
(3) or chemotherapy and DLI (1), all have chronic GVHD. Four
AML pts died from relapse. Projected 2-year disease-free survival
and survival respectively is 72  9% and 80  8% for ALL, 87 
6% and 87  6% for AML. For the combined group the corre-
sponding ﬁgures are 80  8% and 89  6% for MRD and 78 
8% and 78  8% for AD transplants respectively (P  ns). This
regimen appears relatively well tolerated and gives equivalent ﬁnal
outcomes from MRD and AD. If these results can be conﬁrmed the
combination deserves study in children with acute leukemia in
whom the toxicity of higher doses of TBI could be avoided.
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Background: Graft-versus-host disease (GvHD) is a serious
complication after allogeneic hematopoietic stem cell transplanta-
tion (HSCT). Methotrexate in combination with a calcineurin
inhibitor (CM) is considered standard GvHD prophylaxis. Studies
suggest that sirolimus in combination with a calcineurin inhibitor
(SC) is effective in preventing GvHD and minimizing transplant-
related morbidity and mortality. Method: A total of 159 patients
with hematological diseases underwent myeloablative HLA-
matched HSCT with either CM (n 97) or SC (n 62) as GvHD
prophylaxis at the Dana-Farber Cancer Institute between June
2000 and December 2004 using Cytoxan and TBI conditioning.
Inpatient costs for the ﬁrst transplant year of 94 CM and 47 SC
recipients were obtained. We compared inpatient costs and clinical
outcomes for the ﬁrst transplant year between the two different
GvHD prophylaxis groups by use of univariate and multivariate
analyses. Results: CM recipients were more likely to have unre-
lated donors, BM grafts, and to be transplanted in earlier years than
SC recipients. In univariate analysis, the SC regimen was associ-
ated with faster engraftment (13 days vs 17 days, P  .01), less
grade II to IV acute GvHD (18% vs 37%, P .01) and better DFS
(71% vs 52%, P  .01) and OS (72% vs 53%, P  .01). Days of
initial hospitalization and costs within the ﬁrst year were lower for
SC in the univariate analysis (27 days vs 33 days, P  .01, $101697
vs $110081, P  .03, respectively) but not in the multivariate
analysis (ratio (CM vs SC) 0.99, P  .91, ratio 1.14, P  .30,
respectively). Use of an unrelated donor was the only signiﬁcant
predictor of high costs considering baseline patient characteristics.
In contrast, grade II to IV aGvHD, late engraftment, and in-
hospital death were the signiﬁcant factors associated with high
costs considering both baseline patient characteristics and post-
transplant events. Conclusion: Both OS and DFS in the SC group
were higher in the multivariate analysis, probably due to early
engraftment and reduced incidence of grade II to IV aGvHD seen
in SC group. However, we could not detect the impact of GvHD
prophylaxis on inpatient costs for the ﬁrst transplant year. The SC
regimen is a promising alternative to CM and larger multi-center
randomized trial is planned through the NIH-funded Clinical
Trials Network.
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The HCT-CI proved to be a sensitive tool to capture pretrans-
plant comorbidities among patients (pts) given allogeneic HCT at
FHCRC (Blood 2005;106:2912). We sought to validate the effec-
tiveness of the HCT-CI in predicting NRM and survival at an-
other institution (MDACC) and compare its performance to those
of other comorbidity indices. For this purpose, pretransplant co-
morbidities were assessed in pts with acute myeloid leukemia in
ﬁrst remission from FHCRC (n  137) and MDACC (n  70) by
two independent investigators. Comorbidities were scored using
HCT-CI, Charlson comorbidity index (CCI), and the adult co-
morbidity evaluation (ACE-27, a recent modiﬁcation of the
Kaplan-Feinstein Index). Conditioning included myeloablative
(78% and 69% of FHCRC and MDACC pts, respectively) or
reduced intensity regimens. Donor grafts were from related (66%
and 86% of FHCRC and MDACC pts, respectively) or unrelated
donors. Stem cell source was marrow (28% and 60% of FHCRC
and MDACC pts, respectively) or G-PBMC. Among the 207 pts,
35%, 29%, and 36%, respectively, had HCT-CI scores of 0 vs 1-2
vs 3; 83%, 9%, and 8%, respectively, had CCI scores of 0 vs 1 vs
2; and 56%, 28%, and 16%, respectively, had ACE-27 scores of
0 vs 1 vs2. HCT-CI scores of 1-2 and3 were found in 33% and
25% FHCRC pts and 20% and 59% MDACC pts. Cumulative
incidences of 2-year NRM were 5%, 7%, and 24%, respectively,
among FHCRC pts with HCT-CI scores of 0 vs 1-2 vs3 and 7%,
14%, and 31% among their MDACC counterparts. Unadjusted
hazard ratios (HR) for NRM were 1.11 and 4.3 for HCT-CI scores
of 1-2 and 3 among FHCRC pts compared to 2.41 and 5.72
among MDACC pts. Similarly, HR for worse survival were 2.47
and 6.21 for HCT-CI scores of 1-2 and 3 among FHCRC pts
compared to 2.18 and 2.73 among MDACC pts. In multivariable
regression analyses, HCT-CI scores showed the highest prediction
for NRM (HR 5.13, P  .001) and worse survival (HR 4.96, P 
.0001) compared to CCI scores (P  .2 and .05, respectively) and
ACE-27 scores (P .03 and .002, respectively). These results were
further validated separately at each institution (Table 1), where
higher HCT-CI scores showed the highest HR predicting of NRM
and worse survival among FHCRC and MDACC pts compared to
other risk factors. Results conﬁrm the ability of HCT-CI to predict
post-HCT outcomes. The HCT-CI identiﬁed more pts with co-
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